For the more than 50 million Americans living with chronic pain, the question has always been the same: why does it stay? A torn ligament heals. A surgical wound closes. Yet the pain persists, sometimes for years, sometimes for life, long after the original injury has resolved. New research may finally explain why, and the answer is not in the damaged tissue. It is in the brain.
A study published in May 2026 in the Journal of Neuroscience by researchers led by a team at the University of Maryland School of Dentistry has identified a specific neural pathway that appears to function as a gating mechanism for chronic pain. The pathway connects a small, deep brain region called the caudal granular insular cortex (CGIC) to the primary somatosensory cortex (SI), the area responsible for processing touch and sensation. When researchers blocked this connection in rats with nerve injuries, the animals never developed the lasting pain sensitivity that normally follows such damage. When they activated it, pain persisted far beyond the expected recovery window.
A pathway that locks pain in place
The research team, led by Radi Masri and colleagues, used a technique called DREADDs, a form of chemogenetic manipulation that allows scientists to selectively turn specific neural projections on or off using engineered receptors. In rats with sciatic nerve injuries, inhibiting the CGIC-to-SI pathway prevented the development of allodynia, a condition in which normally painless touch becomes agonizing. Activating the same pathway kept pain behaviors going well past the point when they should have faded.
Electrophysiology recordings and immediate early gene mapping confirmed what the behavioral results suggested: CGIC neurons projecting to SI became hyperactive precisely during the window when acute pain transitions into a chronic state. The pathway was not just involved in pain processing. It was driving the shift.
This finding builds on earlier work from the same research group. A prior study, also published in the Journal of Neuroscience, showed that surgical lesions of the CGIC could both prevent chronic pain from developing and reverse it after it had already taken hold. Lesions made before nerve injury stopped allodynia from appearing. Lesions made afterward eliminated pain that had persisted for weeks. Two different methods, chemogenetic and surgical, now point to the same conclusion: the CGIC is not a bystander in chronic pain. It is a required relay station.
A second discovery points to the same principle
Independent confirmation arrived from a separate laboratory. A study published in Nature by Sun et al. described a distinct closed-loop circuit running from the spinal cord to the thalamus, up to the somatosensory cortex, and back down through the lateral superior colliculus to opioid-receptor-expressing neurons in the brainstem. That circuit, mapped by a different research group using its own circuit-dissection methods, showed that the brain can actively sustain pain through self-reinforcing feedback loops that return amplified signals to the spinal cord.
When two independent teams working on different circuits reach the same functional conclusion, the finding carries substantially more weight than any single experiment. Together, these discoveries rewrite a basic assumption about chronic pain: it is not simply acute pain that refuses to stop. It is a distinct brain state, maintained by identifiable circuits that can, in principle, be interrupted.
The gap between rats and patients
All of the primary experimental evidence so far comes from rodent models, and the distance between a rat brain and a human brain is not trivial. A review in Frontiers in Neuroscience that maps the architecture of insular cortex subdivisions across species explicitly flags the differences. The human insular cortex is far more complex, with distinct anterior and posterior regions that do not correspond neatly to rodent anatomy. Whether a functionally equivalent CGIC-to-SI projection exists in the human brain, and whether it behaves the same way during pain chronification, has not been confirmed through direct clinical intervention studies.
That said, human neuroimaging research has provided some relevant evidence. Functional connectivity studies in chronic pain patients have identified altered insular-to-somatosensory cortex connectivity, suggesting that a related pathway may play a role in human pain chronification. However, these imaging findings are correlational and do not establish the same causal relationship demonstrated in the rodent experiments.
The “pain switch” framing also requires careful interpretation. The CGIC-to-SI pathway is better understood as one critical node in a larger network that includes synaptic plasticity changes, long-term potentiation of excitatory transmission in the insular cortex, and top-down modulation of spinal cord signals. Research published in Molecular Pain has shown that the insular cortex can directly alter excitatory transmission in the dorsal spinal cord, suggesting the mechanism operates more like a volume dial embedded in a feedback loop than a binary toggle. The metaphor is useful shorthand, but the biology is more nuanced.
No human clinical trial has tested whether targeting this pathway would relieve chronic pain in patients. The chemogenetic tools used in these studies are not approved for human use, though gene therapy approaches using similar viral vector technology are in clinical trials for other neurological conditions. Translating these findings into treatments would likely require adapting the approach for non-invasive brain stimulation techniques, such as transcranial magnetic stimulation or focused ultrasound, or developing drugs that selectively modulate CGIC-to-SI activity without disrupting normal sensation.
Why these circuits could reshape chronic pain treatment
For the roughly one in five American adults who report chronic pain, according to CDC estimates, current treatment options remain frustratingly limited. Opioids carry addiction risks. Anti-inflammatory drugs often fail to address pain that has no remaining inflammatory source. Physical therapy and cognitive behavioral approaches help some patients but leave many others with unrelenting symptoms. The field has long needed new biological targets, and these studies offer exactly that.
The strongest evidence here is primary and peer-reviewed. The May 2026 study combined pathway-specific chemogenetic tools with electrophysiology and gene expression mapping, a rigorous combination that isolates cause and effect within a single neural projection. The earlier lesion study provides converging evidence using a completely different method. The Nature paper on the spinal feedback loop comes from an independent lab. When multiple lines of evidence from different groups and different techniques converge on the same principle, the science is on solid ground.
Clinical application, however, likely remains years away. No one is going to walk into a pain clinic next month and have their CGIC-to-SI pathway dialed down. But the conceptual shift matters now. For decades, chronic pain has been treated as a problem of damaged tissue sending persistent signals. These findings reframe it as an active brain state, maintained by specific, identifiable neural hardware that could, with the right tools, be switched off. That is not a cure. But it is, for the first time, a concrete address in the brain where a cure might eventually be delivered.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
